SWEDISH ORPHAN BIOVITRUM AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 280.2 SEK | 0.00% |
|
+1.16% | +4.94% |
| May. 24 | Sobi North America Gets FDA Fast Track Designation for Rheumatic Disease Complication Treatment | DJ |
| May. 14 | Swedish Orphan Biovitrum AB Elects Zlatko Rihter as New Board Member | CI |
Evolution of the average Target Price on Swedish Orphan Biovitrum AB
Price target over the last 5 years
History of analyst recommendation changes
f665c779f3576b9.brt-tAuC2-8RRMrjdklaf92MF1ruAlspC3ncz0frB4M.Jd5N4kXVlJx3CKjORWQCSpjdWjKmSA1qZi7qpCSkbtUfjU3XOcudllcMiw~afe2e7c73468af956140005350cfaff9
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
280.2
SEK
Average target price
317.8
SEK
Spread / Average Target
+13.41%
High Price Target
370
SEK
Spread / Highest target
+32.05%
Low Price Target
252
SEK
Spread / Lowest Target
-10.06%
Consensus detail
Consensus revision (last 18 months)
Trading Rating
Investor Rating
ESG Refinitiv
B+
EPS Revisions
- Stock Market
- Equities
- SOBI Stock
- Consensus Swedish Orphan Biovitrum AB
